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Background: Banding-karyotyping and metaphase-directed-fluorescence-in-situhybridization (FISH) may be hampered
by low mitotic index in leukemia. Interphase FISH (iFISH) is a way out here, however, testing many probes at the
same time is protracted and expensive. Here multiplex-ligation-dependent-probe-amplification (MLPA) was used
retrospectively in chronic lymphocytic leukemia (CLL) samples initially studied by banding cytogenetics and iFISH.
Detection rates of iFISH and MLPA were compared and thus a cost-efficient scheme for routine diagnostics is
proposed.
Results: Banding cytogenetics was done successfully in 67/85 samples. DNA was extracted from all 85 CLL samples.
A commercially available MLPA probe set directed against 37 loci prone to be affected in hematological malignancies
was applied. Besides, routine iFISH was done by commercially available probes for following regions: 11q22.3,
12p11.2-q11.1, 13q14.3, 13q34, 14q32.33 and 17p13.1. MLPA results were substantiated by iFISH using
corresponding locus-specific probes.
Aberrations were detected in 67 of 85 samples (~79%) applying banding cytogenetics, iFISH and MLPA. A
maximum of 8 aberrations was detected per sample; however, one aberration per sample was found most
frequently. Overall 163 aberrations were identified. 15 of those (~9%) were exclusively detected by banding
cytogenetics, 95 were found by MLPA (~58%) and 100 (~61%) by routine iFISH. MLPA was not able to distinguish
reliably between mono- and biallelic del(13)(q14.3q14.3), which could be easily identified as well as quantified
by routine iFISH. Also iFISH was superior to MLPA in samples with low tumor cell load. On the other hand
MLPA detected additional aberrations in 22 samples, two of them being without any findings after routine iFISH.
Conclusions: Both MLPA and routine iFISH have comparable detection rates for aberrations being typically
present in CLL. As MLPA can detect also rare chromosomal aberrations it should be used as an initial test if
routine cytogenetics is not possible or non-informative. Still iFISH should be used additionally to distinguish
mono- from biallelic deletions and also to determine rate of mosaicism for 13q14.2 to 13q14.3. In case MLPA is
negative the corresponding CLL samples should be tested at least by iFISH using the standard probe set to.
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Figure 1 Number of aberrations present per sample as found in
this study after application of all mentioned methods (banding
cytogenetics, iFISH and MLPA) – values given in percent.
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Chronic lymphocytic leukemia (CLL) is considered as the
most common adult leukemia in Western countries with
an estimated incidence of 5.8 in men and of 3.0 in women
per 100,000 individuals and per year. It predominantly af-
fects persons with more than 50 years of age [1,2]. A hall-
mark of CLL is the presence of cytogenetic abnormalities;
the latter help to estimate a patient’s prognosis more ac-
curately and also may provide insights into disease patho-
genesis [3]. However, banding cytogenetics can only detect
aberrations in ~30% of CLL samples [4]. Still, according to
molecular (cyto)genetic data the major recurrent aberra-
tions are:
(i) Deletions in 13q14 (50-60% of the samples)
associated with a good prognosis, as are deletions in
14q32.33 (12-15% of the samples);
(ii) Trisomy 12 (15-25%) associated with intermediate
prognosis; and
(iii) Deletions in 11q22 (ATM) (10-20%) or 17p13
(TP53) (5-10%) and/or recurrent balanced
translocations go together with adverse prognosis
[4-9];
(iv) Less frequently observed aberrations in CLL are
deletions in 6q associated with intermediate
prognosis, 9p21 and 10q23, total or partial
trisomies of chromosomes 3, 8, 18, or 19, and
duplications in 2p24, the prognostic significance for
these aberrations is unknown [1,10,11].
These aberrations were either detected applying cytogen-
etics and/or interphase fluorescence in situ hybridization
(iFISH) [3] or more recently multiplex ligation-dependent
probe amplification (MLPA) [7]. While iFISH provides in-
formation only for a limited number of genomic targets at
the same time [1,5,7] MLPA can detect copy number al-
terations, methylation pattern changes and/or even point
mutations simultaneously in multiple target regions [7,12].
Still iFISH can more reliably detect low level mosaics and
mosaics of mono- and biallelic deletions [13].
In this study the efficiency of MLPA was compared with
yet in our lab routinely performed cytogenetic and iFISH
diagnostics of CLL. Based on the obtained results a new
diagnostic scheme is proposed combining MLPA and
iFISH leading to a more comprehensive characterization
of each individual sample.
Results
85 samples of patients suffering from CLL (Additional
file 1: Table S1 and Additional file 2: Table S2) were stud-
ied here. Overall, including results from all here applied
tests, chromosomal aberrations were detected in 70/85
(~85%) of the studied CLL-samples (Additional file 1:
Table S1 and Additional file 2: Table S2). As summarizedin Figure 1 between 0 and 8 aberrations were detectable
per case. One chromosomal rearrangement per sample
could be found most often (40%), followed by no aberra-
tion at all and three aberrations per sample. Four or more
aberrations per sample were found in less then 10% of
the cases.
Overall, 163 aberrations were detected in the 85 studied
samples (Table 1, Additional file 2: Table S2). Cytogenet-
ics revealed aberrant karyotypes in 15 (~22%) of the 67
samples where corresponding analyses was successful
(Additional file 1: Table S1). In parts the cytogenetic find-
ings could be substantiated by iFISH and or MLPA. As no
corresponding probes were included neither in routine
iFISH nor in MLPA, 15 (~9%) of the 163 detected ab-
errations were found additionally by cytogenetics (Table 2).
Interestingly, in sample 57 which presented with 5
chromosomal aberrations after banding cytogenetics no
aberrations could be detected at all by iFISH or by MLPA.
Other samples gave either no, a normal cytogenetic result
or a result which also was confirmed by MLPA and/or
iFISH (Additional file 1: Table S1).
Concerning the detection rates, the applied MLPA test
found ~58% and routine iFISH ~61% of the 163 aberrations
(Table 1, Additional file 2: Table S2). del(13)(q14.3q14.3)
was most frequently found, i.e. in ~28% of the samples),
followed by del(11)(q22.3q22.3) in ~9%, del(14)(q32q32)
in ~8%, and del(13)(q14.2q14.2) and del(17)(p13.1p13.1)
in ~6% of the samples, each.
Discordant results of MLPA and routine iFISH were in
parts due to the different target regions covered by the
tests; thus e.g. del(14)(q32q32) were only detectable by
routine iFISH. On the other hand, MLPA detected add-
itional aberrations in 22 samples, three of the patients
being without any aberrant findings according to routine
iFISH (Additional file 2: Table S2, cases 68–70).
In Table 3 thirteen samples are listed, which had low
level mosaic aberrations based on routine iFISH and were
not picked up by MLPA. In contrary in Table 4 twelve
other samples with similar low level mosaics are listed,
which were picked up by MLPA.
Table 1 Summary of 99 aberrations as detected by MLPA
and 146 ones as detected or confirmed by iFISH; samples
contributing to the discordant results of MLPA and iFISH
are marked with asterisk *, ** or ‘plus-sign’ +




amp(2)(p24.3p24.3) MYCN 3 3
amp(2)(p23.2 ~ 23.1p23.2 ~ 23.1) ALK 3 3
del(6)(q21q21) FYN 1 1
del(6)(q23.3q23.3) MYB 2 2
del(6)(q25.1q25.1) ESR1 1 1
del(6)(q27q27) SMOC2 1 1
amp(6)(q27q27) SMOC2 1+ 0
amp(8)(q24.21q24.21) MYC 1 1
t(9;22)(q34;q11) BCR and ABL n.a. 1
del(11)(q22.3q22.3) ATM 12 14*
+12 ETV6, CCND2, 4 6*
MDM2
del(13)(q14.2q14.2) RB1 10 11**
del(13)(q14.2q14.2)x2 RB1 1 10**
del(13)(q14.3q14.3) DLEU1, DLEU2, 35 46*/**
MIR15A
del(13)(q14.3q14.3)x2 DLEU1, DLEU2, 7 14**
MIR15A
del(14)(q32q32) IGH n.a. 13
rea(14)(q32.33) - > t(14;?) IGH n.a. 2
rea(14)(q32.33) - > ? + 14 IGH n.a. 1
del(17)(p13.1p13.1) TP53 9 10*
amp(17)(q25.1q25.2) UNC13D 2 2
amp(18)(p11.21q11.21) DCC 2+ 1
amp(18)(q21.2q21.2) RNMT 2+ 1
amp(21)(q22.12q22.12) RUNX1 2 2
Those with * are detailed in Table 2, those with ** in Table 4. Those with + could
either not be tested in iFISH due to lack of corresponding probe or, in the two
of the tested samples MLPA could not be confirmed by iFISH (routine and
confirmatory together), most likely due to too large FISH-probe size.
Table 2 Aberrations only detected by banding
cytogenetics in 9 samples of the present study
















Table 3 Detailed results in samples contributing to the
discordant results of MLPA and iFISH marked with
asterisk * in Table 1




del(11)(q22.3q22.3) ATM 1 30
del(11)(q22.3q22.3) ATM 2 33
+12 ETV6, CCND2, MDM2 3 15
+12 ETV6, CCND2, MDM2 4 31
del(13)(q14.3q14.3) DLEU1, DLEU2, MIR15A 5 18
del(13)(q14.3q14.3) DLEU1, DLEU2, MIR15A 6 10
del(13)(q14.3q14.3) DLEU1, DLEU2, MIR15A 7 10.5
del(13)(q14.3q14.3) DLEU1, DLEU2, MIR15A 8 12
del(13)(q14.3q14.3) DLEU1, DLEU2, MIR15A 9 18.5
del(13)(q14.3q14.3) DLEU1, DLEU2, MIR15A 10 25
del(13)(q14.3q14.3) DLEU1, DLEU2, MIR15A 11 34
del(13)(q14.3q14.3) DLEU1, DLEU2, MIR15A 12 34
del(17)(p13.1p13.1) TP53 13 11.5
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carrying deletions in 13q14.2 and/or 13q14.3 according
to MLPA and iFISH. Still iFISH revealed that there was
a mix of monoallelic and biallelic deletion or only biallelic
deletion, which could not always be detected by MLPA
(Additional file 2: Table S2). Only such cases which had
100% biallelic deletions could be identified undoubtedly
(e.g. sample 30); others showed biallelic deletions in
MLPA but were indeed a mix of mono- and biallelic ones.
Finally, three copy number alterations found by MLPA
could not be substantiated by additional iFISH studies
(samples 65–67; Additional file 2: Table S2).
In Figure 2 a flow is suggested how a CLL-characterization
could be performed most comprehensively and straightforward. Figure 3 shows how cases would have been
grouped if only cytogenetics, only MLPA or only iFISH
would have been done. Tables 6, 7 and 8 highlights how a
step by step characterization and corresponding new re-
sults of would change the prognosis of the 95 studied
cases.
Discussion
When diagnostic screening for acquired genetic alter-
ation in hematological malignancies is to be done, band-
ing cytogenetics is still the gold standard, as it enables
Table 4 Detailed results in samples with concordance of
MLPA and routine iFISH results but mosaic rates below
40% according to iFISH




del(11)(q22.3q22.3) ATM 14 23.5
del(11)(q22.3q22.3) ATM 15 24
del(11)(q22.3q22.3) ATM 16 11
del(13)(q14.3q14.3) DLEU1, DLEU2, MIR15A 1 30
del(13)(q14.3q14.3) DLEU1, DLEU2, MIR15A 2 18
del(13)(q14.3q14.3) DLEU1, DLEU2, MIR15A 4 20
del(13)(q14.3q14.3) DLEU1, DLEU2, MIR15A 14 34
del(13)(q14.3q14.3) DLEU1, DLEU2, MIR15A 17 20
del(17)(p13.1p13.1) TP53 1 16
del(17)(p13.1p13.1) TP53 12 21
del(17)(p13.1p13.1) TP53 18 19
del(17)(p13.1p13.1) TP53 19 36
Table 5 Combination of biallelic and/or monoallelic
deletion del(13)(q14.2q14.2) and del(13)(q14.3q14.3) –















2 0 0 18 14
4 45 0 20 0
12 52 38 34 0
13 0 0 0 98.5
20 0 0 0 94
21 50 30 0 91
22 0 0 5 75
23 0 0 5 81
24 36 41 16 71
25 66 21 18 77
26 0 0 25 65
27 34 27 36.5 24
28 0 0 81 7
29 58 24 86 9
30 0 0 0 100
54 41 39 97 0
55 73 5 85 0
56 22 58 12 66
63 51 38 90 0
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[14]. Malignant CLL cells derived from bone marrow are
known to have a low mitotic index and in many cases only
cytogenetically normal cells can be analyzed [4]. Thus,
iFISH and MLPA are routinely applied additionally to or
even as a replacement in tumorcytogenetics of CLL [7,15].
In this study, after directed diagnostics for 37 genetic
loci (MLPA and routine iFISH together), still ~18% of the
samples remained without an identified tumor marker. As
highlighted by samples 32, 34, 41, 36 (see as well [16]) 38,
57, 58, 61 and 70 this can be due to unusual, not by tar-
geted routine tests covered chromosomal aberrations; be-
sides submicroscopic aberrations like point mutations [2]
could be present in those ‘normal’ samples. Interestingly,
in over 40% of the studied cases more than only one
chromosomal aberration was identified (Figure 1). This
may reflect in parts the slow progress of CLL. I.e. the ma-
lignancy is detected after acquiring multiple aberrations
and not as early as e.g. chronic myelogeneous leukemia
(CML), which is already connected with severe clinical
signs when only a t(9;22) is found, which is the only aber-
ration in majority of the CML-cases [17].
As mentioned above, MLPA and routine iFISH are tar-
geted tests, both. As they cover in parts different loci it
was not unexpected that they have different detection
rates. However, one would expect that iFISH technique
underestimates the genomic complexity in CLL [1]. Still
it is striking that the routine iFISH test found 61% of the
163 aberrations while MLPA only detected 58%, even
though routine iFISH applied only 5 probes and MLPA
had more than 7 times more, i.e. 37 target regions.
Concerning detection of low level mosaics (10% up to
36% of the cells being aberrant) this study showed that
there are about alike amounts of cases being detectable and
being missed by MLPA (Tables 3 and 4). There were cases
detectable by MLPA with aberrant cell clone sizes down
to ~10% according to iFISH (sample 16) and such being
not detectable (samples 6, 7, and 8). To the best of our
knowledge there are only few previous [18-20] and no
systematic studies for the detection rates of low level
mosaic in MLPA. Véronèse et al. [7] suggested that all
false-negative cases occur in samples with only 12-21% of
aberrant cells; thus they considered MLPA detection to be
reliable when the fraction of aberrant cells is 25-30%,
which is definitely less sensitive than iFISH detection.
Overall, this problem has to be kept in mind when doing
MLPA exclusively in routine diagnostics.
Still, the findings of this study are in concordance with
Stevens-Kroef et al. [21] who claimed an almost perfect
correlation between MLPA and iFISH, as long as identical
genetic regions are tested in MLPA and iFISH. However,
bi- and monoallelic deletions coming together in one sam-
ple are not considered in this kind of comparison. Still, all
apart from three MLPA findings not detectable in the
Figure 2 Suggestion how to proceed when doing MLPA as a primary test after GTG-banding: in case MLPA finds a tumor marker with
adverse prognosis no further iFISH analyses is necessary. In case of an MLPA result suggesting intermediate, unclear or good iFISH for 3 to 6
target regions should be done. A probe for 6q may be also used; however, as case with a del(6q) are rare we would not recommend it at
present as really indicated to be applied. According to the obtained results cases need to be regrouped. Finally, iFISH can be used to subclassify
cases with good prognosis into such with favorable and unfavorable good prognosis.
Figure 3 Detection rates of cytogenetics, MLPA and iFISH as standalone approaches are depicted and compared with overall result
combining all three tests as suggested in Figure 2; the corresponding results obtained in the 85 cases were aligned with and are
expressed as the resulting prognostic relevance of the identified chromosomal aberrations.
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Table 6 Samples from Additional file 2: Table S2 are listed according to the groups suggested in Figure 2
Results according to
MLPA
Adverse prognosis Intermediate or
unclear prognosis
Good prognosis including groups
“favorable” and “unfavorable”
No aberrations
Samples 1, 10, 12, 14, 15, 16, 17, 18, 19,
24, 34, 35, 38, 39, 54, 58, 61,
63, 64, 65,
5, 37, 62, 68 2*, 4*, 13*, 20*, 21*, 22*, 23*, 25*, 26*,
27*, 28*, 29*, 30*, 40, 41, 42, 43, 44,
45, 46, 47, 48, 49, 50, 51, 52, 53, 55*,
56*, 66, 67, 69
3, 6, 7, 8, 9, 11, 31, 32, 33, 36,
57, 59, 60, 70, 71, 72, 73, 74,




20 4 32 29
Number of samples
per group (percent)
23.5 5 37.5 34
Samples marked with * have biallelic deletion in 13q14 as substantiated by iFISH or deletion of 13q14.2 and 13q14.3, thus going from favorable to unfavorable
subgroup within good prognosis group after iFISH (see Table 7). Figures printed not bold and not in italics are case numbers; figures printed bold and in italics
are absolute numbers of samples or same numbers in percent.
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quent targeted iFISH. In the not verified cases this can be
due to too small size of the detected copy number alter-
ation, not resolvable by iFISH.
It is well known that there are different clinical prog-
noses if a del(13)(q14.3q14.3) comes mono- or biallelic
and alone or together with a del(13)(q14.2q14.2): larger
deletions like del(13)(q14.2q14.3) and biallelic deletions
have shorter time to first treatment [1,22,23]. To get re-
liable information for this question a combination of
MLPA and FISH is necessary.
According to Campregher and Hamerschlak [2] the de-
tected aberrations can be grouped in such with adverse,
intermediate, good prognosis. Those cases with good prog-
noses are further subdivided in such cases with favorable
and such with less favorable outcome. Especially cases with
adverse prognosis have influence on the therapeutic deci-
sions. Taken together with the results of this study we sug-
gest a diagnostic flow as shown in Figure 2.
As both MLPA and routine iFISH have in principle
comparable detection rates in CLL, MLPA is more cost ef-
ficient than iFISH and it covers a more broad spectrum
of target genes [12], we recommend MLPA to be the
initial diagnostic test. The impact for the patient car-
rying rare mutations can be evident: Fabris et al. [11]
reported that 2p gain can be present already in earlyTable 7 Regrouping of samples from Table 6 after doing add
Results according to MLPA Adverse prognosis Intermedi
prognosis
Samples 1+, 2, 3+, 10, 12, 13, 14, 15, 16,
17, 18, 19, 24, 34, 35, 38, 39,
54, 58, 60+, 61, 63, 64, 65,







Samples marked with + have rea(14)(q32.33), thus they have to go to the adverse p
MLPA and/or deletion of 13q14.3 in ≥70% of the nuclei detected by iFISH go to un
not in italics are case numbers; figures printed bold and in italics are absolute numstages of the disease, particularly in those cases character-
ized by other poor prognostic markers (samples 5, 16 and
63); del(6q) is generally considered as an intermediate-risk
factor [1,10] (samples 5 and 68); finally, López et al. [24]
reported more rapid disease progression if trisomy 12 is
accompanied by additional aberrations rather than if it is
the only genetic abnormality (sample 62). Also new data
may be acquired, as e.g. the impact of gain of MYC [1]
(sample 16) or RUNX1 gene [25] (samples 5 and 69) are
still unclear in CLL. If the diagnostic scheme suggested in
Figure 2 would have been applied in the 85 patients pre-
sented here in 20 of them (23.5%) no iFISH would have
been necessary. In those 20 patients (Tables 6, 7 and 8)
MLPA would have already identified one or more ad-
verse chromosomal aberrations leading to a therapeutic
consequence.
Four patients (Tables 6, 7 and 8) would have been grouped
into ‘intermediate prognosis’ after MLPA, one of them just
having a trisomy 12 (sample 37). So in this group of pa-
tients, only three probes for the adverse prognosis regions
should be applied in iFISH testing.
Normal MLPA result as found in 29 samples (= ~34%)
all six (or seven, see legend of Figure 2) FISH probes
as listed in Figure 2 should be applied to rule out low
level mosaics of del(11)(q22.3q22.3), +12, del(13)(q14),






, 68 20, 21, 22, 23, 25, 26, 27,
28, 29, 30, 43, 44, 45, 46,
47, 48, 49, 50, 51, 52, 53,
55, 56, 66, 67
6, 7, 8, 9, 11, 31,
32, 33, 40, 41,
42, 59, 69
36, 57, 70, 71, 72,
73, 74, 75, 76, 77,




rognosis group. Samples with deletion of 13q14.2 and 13q14.3 detected by
favorable subgroup within good prognosis group. Figures printed not bold and
bers of samples or same numbers in percent.
Table 8 Final result after including result of GTG-banding based on from Tables 6 and 7
Results according to
MLPA







Samples 1, 2, 3, 10, 12, 13, 14, 15, 16,
17, 18, 19, 24, 34, 35, 38, 39,
54, 57*, 58, 60, 61, 63, 64, 65, 70*
4, 5, 36*, 37, 62, 68 20, 21, 22, 23, 25, 26, 27, 28,
29, 30, 43, 44, 45, 46, 47, 48,
49, 50, 51, 52, 53, 55, 56, 66, 67
6, 7, 8, 9, 11, 31,
32, 33, 40, 41,
42, 59, 69
71, 72, 73, 74, 75, 76,




26 6 25 13 15
Number of samples
per group (percent)
31 7 30 15 17
Samples marked with * have additional aberration not detectable by MLPA or routine iFISH. Figures printed not bold and not in italics are case numbers; figures
printed bold and in italics are absolute numbers of samples or same numbers in percent.
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samples 3 and 60 to “adverse prognosis” and sample 4 to
“intermediate prognosis” group (Tables 6, 7 and 8).
Finally, 32 patients (Tables 6, 7 and 8) have been classi-
fied as ‘good prognosis’ after MLPA. Here, the same FISH
probes as for normal MLPA result should be used for
further subclassification (Figure 2). Again patients then
may have to be moved to other prognostic groups if
additional or low level mosaics are identified. Also it is
known that CLL cases with del(13)(q14.2q14.2) go into
unfavorable subgroup, as do such cases with biallelic dele-
tions in 13q14. Finally, del(13)(q14.3q14.3) detected in ≥70%
of the cells are also an indication to group a patient in
unfavorable subgroup of ‘good prognosis’ group [1,22]. Thus,
further I-FISH studies are necessary also for patients with
del(13)(q14.2q14.2) and/or del(13)(q14.3q14.3) in MLPA.
In case only MLPA and iFISH would have been done in
the presently studied 85 patient still 3 samples would have
been misclassified. Thus we suggest in Figure 2 still GTG-
banding as the initial test for CLL diagnostics. Compared to
a flow just applying banding cytogenetics and routine iFISH
for diagnostics of CLL the introduction of the flow from
Figure 2 would apply only 344 instead of 425 FISH-probes,
i.e. 20% less.
Conclusion
The present study shows the importance of combining
cytogenetics, molecular genetics and molecular cyto-
genetics to achieve a comprehensive characterization of
acquired genetic alterations being present in CLL.
Methods
Patients and sample preparation
The present study included 85 samples of patients suffer-
ing from CLL (Additional file 1: Table S1 and Additional
file 2: Table S2) diagnosed according to standard criteria
[26]. The samples were obtained under informed consent
of the corresponding patients and according to institu-
tional ethical committee guidelines (Ethical commitee of
the Friedrich Schiller University Jena).
DNA from lymphocytes was extracted by a commer-
cial kit (Qiagen, Hilden, Germany) and was derived fromdifferent sources: 2 samples from heparinized bone mar-
row, 8 samples from heparinized blood, and 75 samples
from cytogenetically prepared cells fixed in methanol/
acetic acid (3:1) – 48 of them derived from bone marrow
and 27 from blood (Additional file 1: Table S1).
GTG-banding and FISH analysis
The blood or bone marrow samples were stimulated with
phorbol ester, i.e. 12-O-tetradecanoylphorbol-13-acetate
(TPA) and cultivated for 96 hours, and a standard cyto-
genetic cell preparation following air drying method was
done [27]. GTG-banding and iFISH analyses were rou-
tinely done in each sample following standard procedures
[27,28]. In 67 samples chromosomes could be obtained
from the material prepared.
For routine iFISH the following commercially available
probe sets (Abbott/Vysis, Wiesbaden, Germany) were used:
LSI p53/LSI ATM (in 17p13.1 and 11q22.3), LSI D13S319/
LSI 13q34/CEP 12 (in 13q14.3, 13q34 and 12p11.1-q11.1),
and LSI IGH dual color, break-apart probe (in 14q32.33).
Additionally, the following probes were used to validate
and possibly confirm the results of MLPA:
– from Abbott/Vysis (Wiesbaden, Germany): LSI 13
(RB1 in 13q14.2), CEP 6 (D6Z1 in 6p11.1-q11,1),
CEP 17 (D17Z1 in 17p11.1-q11.1) and CEP 18
(D18Z1 in 18p11.1-q11.1);
– from Zytovision (Bremerhaven, Germany):
ZytoLight ®SPEC ALK Dual Color Break Apart
(in 2p22.32 ~ 22.31), ZytoLight ®SPEC NMYC/2q11
Dual Color (in 2q24.3 and 2q11), ZytoLight ®SPEC
MYB Dual Color Break Apart (in 6q23.3), ZytoLight
®SPEC ESR1/CEN 6 Dual Color (in 6q25.1 and
6p11.1-q11.1), ZytoLight ®SPEC CMYC/CEN 8 Dual
Color (8q24.21 and 8p11.1-q11.1), ZytoLight ®SPEC
ETV6/RUNX1 Dual Color Dual Fusion (in 12p13.2
and 21q22.12); and
– BACPAC Resources Center (Oakland, USA):
RP1-142 L7 in 6q21 (gene FYN), RP11-318A15 in
17q25.1 (gene UNC13D), RP11-346H17 in 18q21.2
(gene DCC), RP11-37D8 in 6q27 (gene SMOC2) and
RP11-411B in 18p11.22 (gene RNMT).
Table 9 Loci addressed in the commercially available
MLPA kit used in this study
Targets Loci Number of probes included in kit
MYCN 2p24.3 2
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nuclei were examined per sample and FISH-probe.
MLPA analysis
MLPA was performed using SALSA MLPA probemix
P377-A1 for Hematological Malignancies Kit from (MRC-
Holland, Amsterdam, The Netherlands). The P377-A1
probemix kit contains probes for 37 genes covered by
overall 52 probes, which have diagnostic or prognostic
significant role in hematologic malignancies (see Table 9).MLPA was performed according to the manufacturer’s
protocol, which includes three reaction phases: hybridization,
ligation, and PCR. Finally, a capillary electrophoresis
was used to separate and analyze MLPA PCR products.
Genemarker software was used to analyze the peak areas
of the MLPA PCR products, and the ratio was normalized
to a healthy control. Threshold of detection was set at
0.65-1.35, to minimize the false positive cases.
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Additional file 1: Table S1. Gender, age and cytogenetic results of the
studied cases/samples.
Additional file 2: Table S2. Aberrations detected in 85 CLL samples
and by which method the corresponding aberrations could be detected.
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